Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Biogen Idec (NQ:BIIB)

227.60 +1.24 (+0.55%)

Streaming Delayed Price Updated: 4:00 PM EDT, Sep 25, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	958,031
Open	228.27
Bid (Size)	227.58 (100)
Ask (Size)	227.93 (100)
Prev. Close	226.36
Today's Range	223.76 - 228.92
52wk Range	135.39 - 229.19
Shares Outstanding	146,800,000
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Biogen (NASDAQ:BIIB) Q2 Earnings: Leading The Therapeutics Pack

September 24, 2026

As the Q2 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the therapeutics industry, including Bioge...

Via StockStory

Winners And Losers Of Q2: Amgen (NASDAQ:AMGN) Vs The Rest Of The Therapeutics Stocks

September 23, 2026

As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q2. Today, we are looking a...

Via StockStory

Performance

YTD	+28.0%	+28.0%
1 Month	+3.0%	+3.0%
3 Month	+5.4%	+5.4%
6 Month	+23.8%	+23.8%
1 Year	+67.8%	+67.8%

More News

Reflecting On Therapeutics Stocks’ Q2 Earnings: AbbVie (NYSE:ABBV)

September 21, 2026

Via StockStory

Phase 3 Pediatric EMPAVELI Data Published in Clinical Journal of the American Society of Nephrology Show Reduction in Proteinuria and Stabilized Kidney Function in Adolescents with C3G or Primary IC-MPGN

September 17, 2026

From Biogen Inc.

Via GlobeNewswire

Biogen (NASDAQ:BIIB) Shows Strong Technical Breakout Setup With Perfect Trend Rating ↗

August 17, 2026

Via Chartmill

Biogen Eyes Wave of Phase III Readouts as It Expands Beyond Neuroscience ↗

September 15, 2026

Via MarketBeat

Biogen Sees Pivotal Pipeline Moment as It Expands Beyond Neurology ↗

September 12, 2026

Via MarketBeat

Thursday's session: top gainers and losers in the S&P500 index ↗

September 10, 2026

Via Chartmill

Q2 Rundown: Vertex Pharmaceuticals (NASDAQ:VRTX) Vs Other Therapeutics Stocks

September 09, 2026

Via StockStory

Therapeutics Stocks Q2 Teardown: United Therapeutics (NASDAQ:UTHR) Vs The Rest

September 08, 2026

Via StockStory

A Micro-Cap Biotech Just Cleared a Milestone Most Never Reach

September 08, 2026

Via Investor Brand Network

InvestorNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) Gains Editorial Spotlight Following FDA Clearance for Lucid-MS Phase 2 Trial

September 08, 2026

Via Investor Brand Network

InvestorNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Gains Editorial Spotlight Following FDA Clearance for Lucid-MS Phase 2 Trial

September 08, 2026

Via Investor Brand Network

MissionIRNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Gains Editorial Spotlight Following FDA Clearance for Lucid-MS Phase 2 Trial

September 08, 2026

Via Investor Brand Network

A Micro-Cap Biotech Just Cleared a Milestone Most Never Reach

September 08, 2026

From BioMedWire

Via GlobeNewswire

Therapeutics Stocks Q2 Recap: Benchmarking Myriad Genetics (NASDAQ:MYGN)

September 07, 2026

Via StockStory

Stoke Therapeutics and Biogen Present Long-Term Clinical Data that Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC)

September 03, 2026

From Biogen Inc.

Via GlobeNewswire

September 03, 2026

From Stoke Therapeutics, Inc.

Via Business Wire

Stoke Therapeutics and Biogen Announce Presentations of Clinical Data from Studies of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC)

September 01, 2026

From Stoke Therapeutics, Inc.

Via Business Wire

September 01, 2026

From Biogen Inc.

Via GlobeNewswire

Q2 Earnings Highlights: Moderna (NASDAQ:MRNA) Vs The Rest Of The Therapeutics Stocks

August 27, 2026

Via StockStory

Unpacking Q2 Earnings: Novavax (NASDAQ:NVAX) In The Context Of Other Therapeutics Stocks

August 25, 2026

Via StockStory

3 Reasons to Sell BIIB and 1 Stock to Buy Instead

August 25, 2026

Via StockStory

Therapeutics Stocks Q2 Results: Benchmarking BioMarin Pharmaceutical (NASDAQ:BMRN)

August 19, 2026

Via StockStory

Biogen (BIIB) Q2 2026 Earnings Call Transcript ↗

August 07, 2026

Via The Motley Fool

Frequently Asked Questions

Is Biogen Idec publicly traded?

Yes, Biogen Idec is publicly traded.

What exchange does Biogen Idec trade on?

Biogen Idec trades on the Nasdaq Stock Market

What is the ticker symbol for Biogen Idec?

The ticker symbol for Biogen Idec is BIIB on the Nasdaq Stock Market

What is the current price of Biogen Idec?

The current price of Biogen Idec is 227.60

When was Biogen Idec last traded?

The last trade of Biogen Idec was at 09/25/26 04:00 PM ET

What is the market capitalization of Biogen Idec?

The market capitalization of Biogen Idec is 33.41B

How many shares of Biogen Idec are outstanding?

Biogen Idec has 33B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

More ways to get to us

Facebook

Twitter

YouTube

About Us

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433